ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ICLR
- CUSIP: N/A
- Web: www.iconplc.com
- Market Cap: $5.35653 billion
- Outstanding Shares: 53,775,000
- 50 Day Moving Avg: $97.39
- 200 Day Moving Avg: $86.90
- 52 Week Range: $72.70 - $101.40
Sales & Book Value:
- Trailing P/E Ratio: 20.55
- Foreward P/E Ratio: 17.34
- P/E Growth: 1.34
- Annual Revenue: $1.7 billion
- Price / Sales: 3.13
- Book Value: $17.56 per share
- Price / Book: 5.64
- EBIDTA: $388.4 million
- Net Margins: 16.15%
- Return on Equity: 28.89%
- Return on Assets: 14.94%
- Debt-to-Equity Ratio: 0.37%
- Current Ratio: 1.91%
- Quick Ratio: 1.91%
- Average Volume: 374,465 shs.
- Beta: 0.59
- Short Ratio: 4.24
Frequently Asked Questions for Icon Plc (NASDAQ:ICLR)
What is Icon Plc's stock symbol?
Icon Plc trades on the NASDAQ under the ticker symbol "ICLR."
How were Icon Plc's earnings last quarter?
Icon Plc (NASDAQ:ICLR) announced its quarterly earnings results on Thursday, April, 27th. The company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.27 by $0.02. The business earned $432 million during the quarter, compared to analysts' expectations of $432.21 million. Icon Plc had a net margin of 16.15% and a return on equity of 28.89%. The firm's revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.12 EPS. View Icon Plc's Earnings History.
What guidance has Icon Plc issued on next quarter's earnings?
Icon Plc updated its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $5.06-5.26 for the period, compared to the Thomson Reuters consensus estimate of $5.09. The company issued revenue guidance of $1.70-1.75 billion, compared to the consensus revenue estimate of $1.72 billion.
Where is Icon Plc's stock going? Where will Icon Plc's stock price be in 2017?
9 equities research analysts have issued 1 year price objectives for Icon Plc's stock. Their predictions range from $66.00 to $117.00. On average, they expect Icon Plc's share price to reach $94.50 in the next year. View Analyst Ratings for Icon Plc.
Are investors shorting Icon Plc?
Icon Plc saw a decrease in short interest during the month of June. As of June 15th, there was short interest totalling 1,741,183 shares, a decrease of 19.6% from the May 31st total of 2,166,036 shares. Based on an average trading volume of 349,587 shares, the days-to-cover ratio is presently 5.0 days. Currently, 3.3% of the company's shares are short sold.
Who are some of Icon Plc's key competitors?
Some companies that are related to Icon Plc include Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX) and Sage Therapeutics (SAGE).
Who are Icon Plc's key executives?
Icon Plc's management team includes the folowing people:
- Ciaran Murray, Chairman of the Board
- Steve Cutler, Chief Executive Officer, Director
- Brendan Brennan, Chief Financial Officer
- Diarmaid Cunningham, Executive Vice President, General Counsel, Secretary
- Hugh Brady, Non-Executive Director
- John Climax, Non-Executive Director
- William W. Hall M.D., Ph.D., Non-Executive Director
- Ronan Lambe Ph.D., Non-Executive Director
- Mary K. Pendergast J.D., Non-Executive Director
Who owns Icon Plc stock?
Icon Plc's stock is owned by a number of of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (4.07%), Peregrine Capital Management LLC (0.62%), Boston Advisors LLC (0.37%), Summit Creek Advisors LLC (0.30%), Russell Investments Group Ltd. (0.26%) and Bank of Montreal Can (0.26%). View Institutional Ownership Trends for Icon Plc.
Who sold Icon Plc stock? Who is selling Icon Plc stock?
Icon Plc's stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can, Boston Advisors LLC, Acadian Asset Management LLC, Summit Creek Advisors LLC, Parametrica Management Ltd, Campbell & CO Investment Adviser LLC and Independent Portfolio Consultants Inc.. View Insider Buying and Selling for Icon Plc.
Who bought Icon Plc stock? Who is buying Icon Plc stock?
Icon Plc's stock was bought by a variety of institutional investors in the last quarter, including Legato Capital Management LLC, Fox Run Management L.L.C., Russell Investments Group Ltd., Diversified Trust Co, Farmers & Merchants Investments Inc., GW&K Investment Management LLC, Somerset Trust Co and US Bancorp DE. View Insider Buying and Selling for Icon Plc.
How do I buy Icon Plc stock?
Shares of Icon Plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Icon Plc's stock price today?
MarketBeat Community Rating for Icon Plc (NASDAQ ICLR)MarketBeat's community ratings are surveys of what our community members think about Icon Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Icon Plc stock can currently be purchased for approximately $99.01.
Consensus Ratings for Icon Plc (NASDAQ:ICLR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 2.78)|
|Consensus Price Target: ||$94.50 (4.56% downside)|
Analysts' Ratings History for Icon Plc (NASDAQ:ICLR)
(Data available from 7/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/7/2017||Goldman Sachs Group, Inc. (The)||Upgrade||Buy -> Conviction-Buy||$117.00||High|
|6/29/2017||Jefferies Group LLC||Upgrade||Hold -> Buy||$86.00 -> $117.00||Medium|
|6/9/2017||Robert W. Baird||Lower Price Target||Outperform||$107.00 -> $97.00||Low|
|6/6/2017||Credit Suisse Group||Reiterated Rating||Outperform||$91.00 -> $102.00||Low|
|4/28/2017||Evercore ISI||Boost Price Target||Outperform||$91.50 -> $92.00||Low|
|12/16/2016||SunTrust Banks, Inc.||Downgrade||Buy -> Hold||$95.00 -> $80.00||N/A|
|10/20/2016||Avondale Partners||Upgrade||Underperform -> Market Perform||N/A|
Earnings History for Icon Plc (NASDAQ:ICLR)Earnings History by Quarter for Icon Plc (NASDAQ ICLR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/27/2017||3/31/2017||$1.27||$1.29||$432.21 million||$432.00 million||View||N/A|
|2/16/2017||Q416||$1.26||$1.33||$440.78 million||$435.00 million||View||Listen|
|10/20/2016||Q316||$1.18||$1.19||$420.14 million||$420.20 million||View||Listen|
|7/26/2016||Q216||$1.14||$1.14||$409.97 million||$411.00 million||View||Listen|
|4/26/2016||Q116||$1.11||$1.12||$414.35 million||$400.50 million||View||Listen|
|2/23/2016||Q415||$1.10||$1.11||$409.42 million||$403.00 million||View||Listen|
|10/27/2015||Q315||$1.01||$1.02||$399.02 million||$394.70 million||View||Listen|
|7/28/2015||Q215||$0.90||$0.95||$402.15 million||$389.00 million||View||Listen|
|4/28/2015||Q115||$0.81||$0.90||$391.11 million||$388.00 million||View||N/A|
|2/25/2015||Q4||$0.76||$0.87||$391.37 million||$390.10 million||View||N/A|
|10/22/2014||Q314||$0.70||$0.79||$391.12 million||$388.00 million||View||Listen|
|7/30/2014||Q2||$0.58||$0.64||$376.89 million||$376.00 million||View||Listen|
|4/30/2014||Q1||$0.50||$0.57||$352.14 million||$350.00 million||View||Listen|
|2/20/2014||Q413||$0.45||$0.53||$339.86 million||$345.00 million||View||Listen|
|10/24/2013||Q313||$0.41||$0.45||$332.58 million||$339.80 million||View||Listen|
|7/25/2013||Q2 2013||$0.38||$0.43||$321.82 million||$334.20 million||View||Listen|
|4/25/2013||Q1 2013||$0.34||$0.36||$300.81 million||$317.00 million||View||Listen|
|2/19/2013||Q4 2012||$0.33||$0.34||$291.96 million||$300.00 million||View||Listen|
|11/1/2012||Q312||$0.27||$0.29||$282.67 million||$286.00 million||View||N/A|
Earnings Estimates for Icon Plc (NASDAQ:ICLR)
2017 EPS Consensus Estimate: $5.14
2018 EPS Consensus Estimate: $5.58
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Icon Plc (NASDAQ:ICLR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Icon Plc (NASDAQ:ICLR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Icon Plc (NASDAQ:ICLR)
Latest Headlines for Icon Plc (NASDAQ:ICLR)
|Icon Plc (ICLR) Expected to Post Quarterly Sales of $429.66 Million|
www.americanbankingnews.com - July 21 at 7:17 PM
|Wall Street is making huge bets on healthcare companies you've never heard of|
finance.yahoo.com - July 20 at 11:25 PM
| Brokerages Anticipate Icon Plc (ICLR) Will Announce Earnings of $1.30 Per Share|
www.americanbankingnews.com - July 19 at 9:15 AM
|Icon Plc (ICLR) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - July 18 at 12:48 AM
|Undervalued R&D Leader With Great Risk/Reward|
seekingalpha.com - July 10 at 7:41 PM
|Icon Leads The Pack In ROIC, Looks Like Good Value|
finance.yahoo.com - July 10 at 7:40 PM
|ICON Shares Added To Goldman's 'Conviction Buy' List|
finance.yahoo.com - July 8 at 11:39 AM
|Icon Plc (NASDAQ:ICLR) Raised to "Conviction-Buy" at Goldman Sachs Group, Inc. (The)|
www.americanbankingnews.com - July 7 at 8:44 AM
|ICON wins eLearning and Animation Awards for its FIRECREST Digital Solutions|
finance.yahoo.com - July 6 at 5:02 AM
|ICON PLC Expected to Earn FY2018 Earnings of $5.55 Per Share (ICLR)|
www.americanbankingnews.com - July 3 at 9:41 AM
|Icon Plc (NASDAQ:ICLR) Short Interest Update|
www.americanbankingnews.com - July 1 at 7:14 AM
|Jefferies Upgrades ICON plc (ICLR) to Buy|
www.streetinsider.com - July 1 at 12:53 AM
|Jefferies Group Weighs in on ICON PLC's FY2017 Earnings (ICLR)|
www.americanbankingnews.com - June 30 at 9:13 AM
|Jefferies Highlights A Pair Trade In Pharma: Buy ICON, Hold Tight On INC Research|
finance.yahoo.com - June 30 at 12:05 AM
|Jefferies Group LLC Upgrades Icon Plc (ICLR) to Buy|
www.americanbankingnews.com - June 29 at 7:52 AM
|Icon Plc (ICLR) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - June 27 at 11:28 PM
|ICON PLC (ICLR) Expected to Post Quarterly Sales of $429.92 Million|
www.americanbankingnews.com - June 25 at 11:20 AM
|Icon Plc (ICLR) Lifted to Buy at BidaskClub|
www.americanbankingnews.com - June 23 at 8:20 PM
|$1.30 Earnings Per Share Expected for Icon Plc (ICLR) This Quarter|
www.americanbankingnews.com - June 23 at 8:10 AM
|Icon Plc (ICLR) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - June 21 at 12:38 AM
|[$$] Drug-Research Shake Up Continues as Pamplona Reaches Deal to Buy Parexel|
finance.yahoo.com - June 20 at 6:39 PM
|Icon Plc (ICLR) Rating Lowered to Buy at BidaskClub|
www.americanbankingnews.com - June 16 at 9:58 PM
|ICON and DIA Amplify Thought Leadership and Debate with DIA Live 2017|
finance.yahoo.com - June 16 at 6:39 PM
|Healthcare Stocks on Investors' Radar -- PAREXEL, IDEXX Labs, ICON PLC, and PRA Health Sciences|
www.nasdaq.com - June 9 at 11:16 PM
|Icon Plc's (ICLR) Outperform Rating Reiterated at Robert W. Baird|
www.americanbankingnews.com - June 9 at 9:32 PM
|ICON plc (ICLR) PT Raised to $102 at Credit Suisse; Strengthening Fundamentals & Momentum in Biotech Funding|
www.streetinsider.com - June 6 at 11:23 PM
|Icon Plc (ICLR) Given "Outperform" Rating at Credit Suisse Group AG|
www.americanbankingnews.com - June 6 at 3:38 PM
|Reviewing Synageva Biopharma Corp (GEVA) & Icon Plc (ICLR)|
www.americanbankingnews.com - June 4 at 10:44 PM
|Comparing Icon Plc (ICLR) & EXACT Sciences (EXAS)|
www.americanbankingnews.com - June 4 at 8:24 AM
|$429.92 Million in Sales Expected for Icon Plc (ICLR) This Quarter|
www.americanbankingnews.com - June 1 at 1:38 PM
|Icon Plc (ICLR) Stock is Cultivating a Strong Business|
investorplace.com - June 1 at 7:54 AM
|Historically Strong Stocks in June|
finance.yahoo.com - May 31 at 5:47 PM
|ValuEngine Lowers Icon Plc (ICLR) to Hold|
www.americanbankingnews.com - May 31 at 3:50 PM
|$1.30 EPS Expected for Icon Plc (ICLR) This Quarter|
www.americanbankingnews.com - May 30 at 10:00 AM
|Icon Plc (ICLR) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - May 27 at 12:46 AM
|ETFs with exposure to ICON Plc : May 22, 2017|
finance.yahoo.com - May 22 at 5:21 PM
|Jefferies Group LLC Reaffirms "Hold" Rating for Icon Plc (ICLR)|
www.americanbankingnews.com - May 11 at 10:36 AM
|ETFs with exposure to ICON Plc : May 4, 2017|
finance.yahoo.com - May 4 at 5:59 PM
|Icon Plc (ICLR) Expected to Announce Earnings of $1.30 Per Share|
www.americanbankingnews.com - May 4 at 8:42 AM
|ICON Plc :ICLR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 2, 2017|
finance.yahoo.com - May 2 at 4:17 PM
|First Analysis Equities Analysts Raise Earnings Estimates for Icon Plc (ICLR)|
www.americanbankingnews.com - May 2 at 9:16 AM
|Icon Plc (ICLR) Given Consensus Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - May 2 at 12:28 AM
|ICON Plc – Value Analysis (NASDAQ:ICLR) : May 1, 2017|
finance.yahoo.com - May 1 at 6:24 PM
|FY2018 EPS Estimates for Icon Plc (ICLR) Increased by Analyst|
www.americanbankingnews.com - May 1 at 1:58 PM
|Icon Plc (ICLR) to Post Q3 2017 Earnings of $1.23 Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - May 1 at 9:01 AM
|Q3 2017 Earnings Estimate for Icon Plc (ICLR) Issued By KeyCorp|
www.americanbankingnews.com - May 1 at 9:01 AM
|Icon Plc Forecasted to Earn Q2 2017 Earnings of $1.26 Per Share (ICLR)|
www.americanbankingnews.com - May 1 at 8:11 AM
|Somewhat Positive Media Coverage Likely to Impact Icon Plc (ICLR) Share Price|
www.americanbankingnews.com - April 30 at 12:23 AM
|Edited Transcript of ICLR earnings conference call or presentation 27-Apr-17 1:00pm GMT|
finance.yahoo.com - April 29 at 9:20 AM
|Icon Plc (ICLR) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS|
www.americanbankingnews.com - April 29 at 1:21 AM
Icon Plc (ICLR) Chart for Wednesday, July, 26, 2017